A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer. by Jeon, Y-J et al.
Correction
CELL BIOLOGY
Correction for “A set of NF-κB–regulated microRNAs induces
acquired TRAIL resistance in Lung cancer,” by Young-Jun Jeon,
Justin Middleton, Taewan Kim, Alessandro Laganà, Claudia
Piovan, Paola Secchiero, Gerard J. Nuovo, Ri Cui, Pooja Joshi,
Giulia Romano, Gianpiero Di Leva, Bum-Kyu Lee, Hui-Lung
Sun, Yonghwan Kim, Paolo Fadda, Hansjuerg Alder, Michela
Garofalo, and Carlo M. Croce, which appeared in issue 26, June
30, 2015, of Proc Natl Acad Sci USA (112:E3355–E3364; first
published June 15, 2015; 10.1073/pnas.1504630112).
The editors wish to note that, after this article was published, a
reader noticed that some fragments of text and some sentences in
the introduction, results, and discussion overlap with text from
other articles and were reproduced without quotation marks. The
editors wish to include the relevant text and references below. No
concerns have been raised about the originality of the research or
about the results and conclusions.
In the introduction, some text from sentences 1, 6–8, 12, and
13 overlaps substantially with text from the following work, which
was not originally cited:
Habelhah H (2010) RIP1 cleavage by caspase-8 is essential for TRAIL-induced NF-κB
activation (University of Iowa, Iowa City, IA). Available at grantome.com/grant/NIH/R01-
CA138475-01A1.
In the introduction, sentences 2 and 3 overlap substantially
with text from the following work, which was not originally
cited:
Bellail AC, Olson JJ, Yang X, Chen ZJ, Hao C (2012) A20 ubiquitin ligase–mediated poly-
ubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma.
Cancer Discov 2(2):140–155.
Sentence 4 of the introduction overlaps substantially with text
from the work below, which was not originally cited: “The other
two receptors, DcR1 and DcR2, are ‘decoy receptors’ and lack
the ability to initiate the apoptotic cascade.”
Garofalo M, et al. (2008) MicroRNA signatures of TRAIL resistance in human non-small cell
lung cancer. Oncogene 27(27):3845–3855.
Sentence 16 of the introduction overlaps substantially with text
from the work below, which was not originally cited: “Lung
cancer is the leading cause of cancer-related mortality, not only
in the United States but also around the world.”
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer:
Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594.
Sentence 8 of paragraph 3 in the discussion overlaps sub-
stantially with text from the work below, which was not originally
cited: “TRAFs were initially discovered as adaptor proteins that
couple the TNF receptor family to signaling pathways.”
Bradley JR, Pober JS (2001) Tumor necrosis factor receptor-associated factors (TRAFs).
Oncogene 20(44):6482–6491.
In the discussion, paragraph 3, sentence 21 overlaps substantially
with text from ref. 49 and is now shown with quotation marks below:
“Genetic inhibition of the NF-ĸB pathway affects both the
initiation and the maintenance of lung cancer, identifying this
pathway as a promising therapeutic target [49]” (49).
49. Xue W, et al. (2011) Response and resistance to NF-ĸB inhibitors in mouse models of
lung adenocarcinoma. Cancer Discov 1(3):236–247.
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E2542 | PNAS | March 21, 2017 | vol. 114 | no. 12 www.pnas.org
A set of NF-κB–regulated microRNAs induces acquired
TRAIL resistance in Lung cancer
Young-Jun Jeona, Justin Middletona, Taewan Kima,b, Alessandro Laganàa, Claudia Piovana,c, Paola Secchierod,
Gerard J. Nuovoa, Ri Cuia, Pooja Joshia, Giulia Romanoa, Gianpiero Di Levaa, Bum-Kyu Leee, Hui-Lung Suna,
Yonghwan Kimf, Paolo Faddaa, Hansjuerg Aldera, Michela Garofalog,1, and Carlo M. Crocea,1
aDepartment of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210; bDepartment of Molecular and
Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030; cDepartment of Experimental Oncology and Molecular Medicine,
Start Up Unit, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy;
dDepartment of Morphology and Embryology, Human Anatomy Section, University of Ferrara, 44100 Ferrara, Italy; eDepartment of Molecular Biosciences,
University of Texas at Austin, Austin, TX 78712; fDepartment of Life Systems, Sookmyung Women’s University, Seoul 140-742, Republic of Korea; and
gTranscriptional Networks in Lung Cancer Group, Cancer Research United Kingdom Manchester Institute, University of Manchester, Manchester M20 4BX,
United Kingdom
Edited by Webster K. Cavenee, Ludwig Institute for Cancer Research University of California San Diego, La Jolla, CA, and approved May 28, 2015 (received for
review March 6, 2015)
TRAIL (TNF-related apoptosis-inducing ligand) is a promising anti-
cancer agent that can be potentially used as an alternative
or complementary therapy because of its specific antitumor
activity. However, TRAIL can also stimulate the proliferation of
cancer cells through the activation of NF-κB, but the exact mech-
anism is still poorly understood. In this study, we show that
chronic exposure to subtoxic concentrations of TRAIL results in
acquired resistance. This resistance is associated with the increase
in miR-21, miR-30c, and miR-100 expression, which target tumor-
suppressor genes fundamental in the response to TRAIL. Impor-
tantly, down-regulation of caspase-8 by miR-21 blocks receptor
interacting protein-1 cleavage and induces the activation of NF-κB,
which regulates these miRNAs. Thus, TRAIL activates a positive
feedback loop that sustains the acquired resistance and causes
an aggressive phenotype. Finally, we prove that combinatory
treatment of NF-κB inhibitors and TRAIL is able to revert resistance
and reduce tumor growth, with important consequences for the
clinical practice.
microRNAs | acquired TRAIL-resistance | lung cancer
TRAIL (TNF-related apoptosis-inducing ligand) is a memberof the TNF superfamily and is considered a potential anti-
cancer agent, as it shows selective high cytotoxicity toward tumor
cells and little or no toxicity against normal cells (1). The anti-
cancer activity of TRAIL is ascribable to its ability to induce
apoptosis through the binding of DR4 and DR5 and the re-
cruitment of intracellular apoptosis-initiating caspase-8 through
Fas-associated death domain for the assembly of the death-
inducing signaling complex (DISC). The cleavage of caspase-8
in the DISC is a critical upstream event in TNF family ligand-
induced apoptosis. The other two receptors, DcR1 and DcR2,
are “decoy receptors” and lack the ability to initiate the apoptotic
cascade. Cross-linking of TRAIL to its death receptors leads to
the recruitment of Fas-associated death domain, procaspase-8,
and procaspase-10 to form DISC (2, 3). Recombinant TRAIL
and agonistic antibodies directed at DRs in phase-II clinical
trials have shown monotherapy activity with isolated responses
reported in follicular lymphoma (4), adenocarcinoma of the lung
(5), and synovial sarcoma (6).
However, recent studies have demonstrated that many types of
cancer cells possess primary or acquired resistance to TRAIL.
Moreover, TRAIL has been found to activate a prosurvival
transcription factor, NF-κB, and enhance metastasis in apopto-
sis-resistant cancer cells (7–9). Receptor interacting protein
(RIP) kinases constitute a family of seven members, all of which
contain a kinase domain. These kinases are crucial regulators of
cell survival and death (10, 11). Particularly, RIP1 serine/threo-
nine kinase plays an important role in the TRAIL dualism. In
apoptosis-sensitive cells, caspase-8 cleaves RIP1 in response to
TNF, resulting in rapid RIP1 depletion and induction of apoptosis.
However, in apoptosis-resistant cells, RIP1 is constitutively active
and activates the NF-κB pathway (10, 12). In line with this finding is
the observation that the activation of NF-κB is blocked by RIP
dominant-negative mutants (13, 14), whereas cultured cells lacking
RIP1 are highly sensitive to TNF-induced cell death, probably be-
cause they are unable to activate the prosurvival transcription factor
NF-κB (15). However, little is known about the involvement of
these proteins in acquired TRAIL resistance.
Lung cancer is the leading cause of cancer-related mortality,
not only in the United States but also around the world. Most
stage-III nonsmall cell lung cancer (NSCLC) express either or
both TRAIL receptors, raising the possibility of using TRAIL as
an anticancer drug, but understanding the molecular mecha-
nisms of primary and acquired TRAIL resistance is necessary for
a successful TRAIL therapy (7, 8). The most well-known small
noncoding RNAs (ncRNAs) are microRNAs (miRNAs), single-
stranded RNAs of 19–25 nt in length that negatively regulate
gene expression by translational inhibition or degradation of the
mRNA target. A large body of evidence suggests that miRNAs
are involved in development of chemosensitivity or resistance in
various tumors (16, 17).
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Here, we show that acquired TRAIL resistance is mediated
by a positive feedback loop involving the NF-κB transcription
factor, miR-21, miR-30c, and miR-100 and their respective targets
caspase-8, caspase-3, Forkhead Box O3a (FoxO3a), and TNF
receptor-associated factor 7 (TRAF-7). Importantly, the com-
bination of TRAIL and NF-κB inhibitors drastically triggers apo-
ptosis in TRAIL-resistant cells in vitro and in vivo, suggesting that
combinatory treatment could be effective in overcoming TRAIL
resistance in lung cancer.
Results
MicroRNA Dysregulation in Cells with Acquired TRAIL Resistance.
Although the many molecules that regulate the TRAIL signaling
cascade are known, the mechanisms by which tumor cells become
more resistant to TRAIL is still not clear. To this end, we gener-
ated TRAIL-resistant cells (H460R and H292R) by exposing H460
and H292-sensitive cells (H460S and H292S) to stepwise increases
in TRAIL concentrations (1–500 ng/mL) over a period of 6 mo to
select cells capable of growing at high concentrations of TRAIL
(Fig. 1A). The establishment of the resistant cells was verified by
counting the apoptotic nuclei after TRAIL treatment (Fig. 1B).
TRAIL receptor isoforms analyzed by Western blot (SI Appendix,
Fig. S1A) or quantitative RT-PCR (qRT-PCR) (SI Appendix, Fig.
S1B) revealed comparable levels of expression in TRAIL-sensitive
and -resistant cells. Moreover, sequencing did not show any mu-
tations, possible because of chronic exposure to the drug, in the
DR4 and DR5 cDNAs of both H460R and H292R compared with
the sensitive parental cells. We have previously reported the in-
volvement of miRNAs in the innate resistance of NSCLC cell lines
to TRAIL (16). Therefore, we analyzed the miRNA expression
profile in H460R versus H460S using the nanoString technology.
Several miRNAs were found dysregulated (Fig. 1C) and we fo-
cused on three miRNAs with the highest fold change in expression:
miR-21, miR-30c, and miR-100. qRT-PCR and Northern blot
analyses confirmed the overexpression of the three miRNAs in
H460R compared with H460S cells (Fig. 1 D and E).
MiR-21, miR-30, and miR-100 Modulate the Response to TRAIL by
Targeting Fundamental Tumor-Suppressor Genes. To investigate
the role of miR-21, miR-30c, and miR-100 in acquired TRAIL
resistance, we overexpressed these miRNAs in H460S cells.
Enforced expression of each individual miRNA drastically re-
duced the sensitivity to TRAIL-induced apoptosis, as assessed by
MTS and caspase-3/7 assays. Moreover, combined ectopic ex-
pression of all three miRNAs further suppressed TRAIL-
induced cell death (Fig. 2A and SI Appendix, Fig. S1C). The
antiapoptotic effect of the three microRNAs was confirmed by
Western blot analysis for poly(ADP-ribose) polymerase (PARP)-1
cleavage (SI Appendix, Fig. S1D). Conversely, knockdown of
miR-21, miR-30c, and miR-100 by anti-miR oligonucleotides in
H460R cells induced a very low proliferation rate (Fig. 2B) and
increased caspase-3/7 activity (SI Appendix, Fig. S1E). Identical
results were obtained in H292S and H292R cells (SI Appendix,
Fig. S1 F–I), suggesting that miR-21, miR-30c, and miR-100
are involved in the resistance to TRAIL-induced cell death. A
Fig. 1. Identification of dysregulated miRNAs in cells with acquired TRAIL resistance. (A) A schematic diagram showing generation of acquired TRAIL-
resistant cells. (B) Cell death measurement of H460R and H292R cells after TRAIL treatment. H406S/R and H292S/R cells were exposed to TRAIL at the indicated
time and concentration. Cell death rates were determined by counting apoptotic nuclei after staining with Hoechst dye. Bars indicate mean ± SD (n = 3). P values
were obtained by two tailed Student t test (*P < 0.01). (C) MiRNA heatmap showing dysregulated miRNAs in H460S versus H460R cells. P values were obtained by
ANOVA test (<0.001). (D) qRT-PCR analysis of miR-21, miR-30c, and miR-100 in H460S/R and H292S/R cells. Bars indicate mean ± SD (n = 3). P values were obtained
by two tailed Student t test (*P < 0.01). (E) Northern blot analysis showing miR-21, miR-30c, and miR-100 up-regulation in H460R compared with H460S cells.
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gene-expression profile was analyzed to highlight the global changes
in gene expression in H460R compared with H460S cells. Down-
regulation of important tumor suppressor genes, such as caspase-8
and caspase-9, and up-regulation of oncogenes, such as PI3K and
Cyclins, were observed (SI Appendix, Fig. S2). Our search for
mRNA targets of miR-21, miR-30c, and miR-100 using Tar-
getscan and Pictar computational tools revealed that 3′ UTRs of
human caspase-8, caspase-3, TRAF-7, and FoxO3a genes con-
tained evolutionarily conserved binding sites specific for these
miRNAs (SI Appendix, Fig. S3A). We focused on these genes
because they are tumor suppressors with defined roles in
apoptosis and in the TRAIL pathway. TRAF-7, the unique, non-
canonical member of the TRAF family, physically associates with
RelA/p65 (p65) member of the NF-κB transcription factor family
inducing its polyubiquitination, which results in lysosomal deg-
radation of the protein, repressing NF-κB activation (18). The
forkhead transcription factors (FoxOs) play pivotal roles in tu-
morigenesis and in mediating chemotherapy sensitivity (19). To
verify that caspase-8, caspase-3, FoxO3a, and TRAF-7 are direct
targets of miR-21, miR-30c, and miR-100, 3′UTRs were cloned
downstream of the luciferase ORF. These reporter constructs
were cotransfected along with the respective miRNA in HEK293
cells. Increased expression of these miRNAs significantly re-
duced luciferase expression, measured as relative luciferase
activity (Fig. 2C). Target gene repression was rescued by deletions
of the complementary seed sites (Fig. 2D), confirming that cas-
pase-8, caspase-3, FoxO3a, and TRAF-7 are direct targets of miR-
21, miR-30c, and miR-100. To determine whether these miRNAs
Fig. 2. MiR-21, miR-30c, and miR-100 confer acquired TRAIL-resistance by silencing caspase-8, caspase-3, FoxO3a, and TRAF-7. (A) Increased cell survival in TRAIL-
sensitive H460 cells in response to TRAIL after miR-21, miR-30c, and miR-100 overexpression or combinatorial expression of the miRNAs. The error bars indicate
mean ± SD (n = 5) and the P values were calculated by two-tailed Student t test (*P < 0.001). (B) Decreased cell survival in TRAIL-resistant cells after miR-21, miR-
30c, and miR-100 knockdown by anti-miR oligonucelotides in response to TRAIL. The error bars indicate mean ± SD (n = 3) and the P values were calculated by
two-tailed Student t test (**P < 0.02). (C and D) caspase-8, caspase-3, FoxO3a, and TRAF-7 3′UTRs are direct targets of miR-21, miR-30c, andmiR-100. pGL3-caspase-
3, pGL3-caspase-8, pGL3-FoxO3a, and pGL3-TRAF-7 luciferase constructs, containing wild-type (C) or mutated (D) 3′UTRs, were transfected into HEK293 cells. Bars
indicate mean ± SD (n = 3) and the P values were addressed by two-tailed Student t test (*P < 0.01, **P < 0.005); ns, not significant. (E) Down-regulation of
caspase-8, caspase-3 FoxO3a, and TRAF-7 by ectopic expression of miR-21, miR-30c, and miR-100. (F) Increased expression of the target genes in lenti–anti-miR-21,
anti–miR-30c, and anti–miR-100 H460R stable infected cells. (G) Coexpression analysis of miRNAs and target genes. The top row shows coexpression analysis of
miR-100 and TRAF-7. The first and third images are the regular light microscopy views after colocalization analysis of the miRNA and protein (RGB). The small
arrows point to the stroma and large arrows to the cancer cells. The other panels show the Nuance fluorescent-based images where the miRNA is fluorescent blue
and the protein fluorescent red. Note that the expression of TRAF-7 and miR-100 are mutually exclusive; strong TRAF-7- expression is seen in the cancer cells in the
first set of images, whereas strong miR-100 expression is seen in the stroma of those images and only in the cancer cells in the last set of images. The second row
shows miRNA-30c (blue/fluorescent blue) and caspase-3 coanalysis (red/fluorescent red). In the first set of images, only caspase-3 expression is evident, whereas in
an adjacent core only miR-30c expression is evident (second set of images). The third row shows the Nuance converted individual protein expression (fluorescent
red), the individual miR-30c (fluorescent blue) and the merged images of miR-30c/FoxO3a and miR-21/caspase-8. Note the lack of coexpression in the merged
images (no fluorescent yellow). The bottom images show coexpression between miR-328 (made by most of the cancer cores) and caspase-8, as a positive control
for coexpressions. The Pearson’s χ2 test was done using the InStat Software for Windows (v3.36) testing the null hypothesis that the probability of the expression
of a given protein (caspase-3, -8, TRAF7, or Fox03a) in cancer cells would be independent of the expression of the specific miRNA of interest. The 2 × 2 table
analysis used the continuity correction and the null hypothesis was rejected if the significance level at 1 df was below 1%. In each case listed the P value for
rejection of the null hypothesis was strongly significant. (Magnification, 400×.)














affect the target gene expression in the H460S cellular envi-
ronment, we analyzed the consequences of their ectopic
expression in H460S cells. MiR-21, miR-30c, or miR-100
enforced expression significantly reduced the endogenous levels
of caspase-8, caspase-3, FoxO3a, and TRAF-7 (Fig. 2E). In-
triguingly, by qRT-PCR, we found that only caspase-3 and cas-
pase-8 (SI Appendix, Fig. S3B) were down-regulated in H460S
cells after miRNA overexpression, indicating that miR-21 and
miR-30c induce the degradation of caspase-8 and caspase-3
mRNAs, whereas FoxO3a and TRAF-7 are regulated at the
translational level. Conversely, stable knockdown of miR-21,
miR-30c, and miR-100 by lentivector-based anti-miRNAs in
H460R cells or knockdown by anti-miR oligonucleotides, con-
firmed by qRT-PCR, increased mRNA (SI Appendix, Fig. S3C)
and protein levels of the target genes (Fig. 2F). To verify these
findings in vivo, in situ hybridization analysis was performed
using 5′-dig-labeled LNA probes on lung cancer tissues, followed
by immunohistochemistry for the target proteins. These analyses
were done initially on serial sections so as to compare the results
on the same groups of cells, followed by coexpression analysis.
Coexpression analysis indicated that when both the miRNA and
protein were found in the same core, they were being expressed
in different groups of cancer cells (Fig. 2G and SI Appendix, Fig.
S3D). Next, to evaluate the contribution of the target genes in
acquired TRAIL resistance, we compared their endogenous
levels in H460R and H292R versus H460S and H292S cells.
Western blot analysis clearly indicated a down-regulation of the
target genes in the resistant cell lines (Fig. 3A). As expected,
caspase-3 and caspase-8 (Fig. 3B) but not FoxO3a and TRAF-7
mRNAs (SI Appendix, Fig. S4A) were also down-regulated in
H460R and H292R cells. Furthermore, enforced expression of
caspase-8, caspase-3, TRAF-7, and FoxO3a in H460R and
H292R cells, decreased cell viability (Fig. 3C and SI Appendix,
Fig. S4B), increased caspase-3/7 activity (Fig. 3D and SI Ap-
pendix, Fig. S4C), and enhanced PARP-1 cleavage (Fig. 3E)
compared with the cells transfected with an empty vector. These
data suggest that these genes play a fundamental role in TRAIL-
induced cell death.
NF-κB Transcriptionally Activates miR-21, miR-30c, and miR-100. The
transcription factor NF-κB is broadly associated with oncogen-
esis, including control of metastasis and angiogenesis (20, 21). It
has been shown that primary TRAIL-resistant cells usually have
higher NF-κB/p65 activity (7, 22–25); therefore, we examined
NF-κB activation in acquired TRAIL-resistant cells. A pGL4.3-
luc2p/NF-κB construct containing five copies of an NF-κB
response element that drives transcription of the luciferase
reporter gene was transfected into H460S and H460R cells
stimulated with TRAIL at different times. Basal NF-κB activity
was higher in H460R compared with H460S cells, with the
highest peak after 3 h of TRAIL treatment. A drop in NF-κB
activity was observed after NF-κB silencing or the overexpression
of dominant active IκB-α (Fig. 4A). Moreover, Western blot
confirmed a higher phosporylation of NF-κB and IKK-α in
H460R cells, whereas IκB-α was down-modulated in H460R cells
after TRAIL stimulation compared with control cells (Fig. 4B).
Similar results were observed in H292R cells (SI Appendix, Fig.
S5A). Next, we analyzed NF-κB nuclear translocation in both
H460S and H460R cells. Cells were incubated with TRAIL for
3 h and then nucleo-cytosol separation was performed. Western
blot showed higher NF-κB expression in the nuclei of H460R
compared with the H460S cells (Fig. 4C). Hundreds of NF-κB
target genes have been identified by ChIP, as well as bio-
informatic analyses based on predicted binding sites. We used a
qRT-PCR array (SABiosciences) to profile the expression of 84
key genes responsive to NF-κB in H460S and H460R (Fig. 4 D
and E). We found that antiapoptotic genes, such as BCL2A1,
BIRC2, XIAP, and genes involved in inflammation and immune
responses were up-modulated in H460R and H292R cells (SI
Appendix, Table S1). In addition, Western blot analysis showed
increased expression of NF-κB transcriptionally activated
TRAIL antagonists, such as Mcl-1 and c-FLIP, which were
Fig. 3. Caspase-8, caspase-3, and TRAF-7 overexpression increases sensitivity to TRAIL in cells with acquired resistance. (A) Down-regulation of caspase-8,
caspase-3, FoxO3a, and TRAF-7 in TRAIL-resistant cells. The bands were quantified by ImageJ software and the relative values normalized by the value of each
GAPDH. (B) qRT-PCR showing caspase-3 and caspase-8 mRNAs down-regulation in H460R compared with H460S cells. (C–E) Proliferation (C), caspase-3/7 assay
(D), and Western blot showing PARP-1 cleavage (E) after caspase-3, caspase-8, and TRAF-7 overexpression in TRAIL-resistant cells. Error bars indicate mean ±
SD (n = 3) and the P values were calculated by two-tailed Student t test (*P < 0.02, **P < 0.01).
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suppressed after NF-κB down-regulations (9, 26–29) in H460R
compared with H460S cells (Fig. 4F). Then, we addressed
whether NF-κB could be involved in miR-21, miR-30c, and miR-
100 transcriptional activation. First, endogenous levels of miR-
21, miR-30c, and miR-100 were higher in TRAIL-resistant
cells following TRAIL-stimulation and consistently decreased
after NF-κB knockdown (Fig. 4G). By bioinformatics search
(PROMO database: alggen.lsi.upc.es/cgi-bin/promo_v3/promo/
promoinit.cgi?dirDB=TF_8.3; TESS database: www.cbil.upenn.edu/
tess), we found that miR-21, miR-30c, and miR-100 had NF-κB
binding sites located ∼−1,280 bp (miR-21), ∼3,730 bp, ∼4,180 bp
(miR-30c), and ∼−3,600 bp (miR-100) upstream of the pre-
miRNAs 5′ ends, respectively. To determine whether the iden-
tified NF-κB sites were located in promoter regions, we cloned
the NF-κB binding sites into the pGL3basic vector, which har-
bors the promoterless luciferase gene. These constructs were
cotransfected along with NF-κB siRNA in H460R cells. Sub-
sequent luciferase assays showed that NF-κB silencing gave rise
to a 40–50% reduction in luciferase activity, whereas inactivation
of the NF-κB binding site by site-direct mutagenesis reduced
luciferase activity compared with cells transfected with NF-κB
wild type (Fig. 4H and SI Appendix, Fig. S5B). Because we
noticed that the promoter regions were responsive to NF-κB
modulation, to verify a direct binding of NF-κB on miR-21, miR-
30c, and miR-100 promoters we carried out ChIP assays. As
expected, ChIP assays of H460R cells showed considerable
NF-κB binding at the predicted analyzed regions for miR-21,
miR-30c, and miR-100 (Fig. 4I). Taken together, these data led us to
conclude that NF-κB is the transcription factor responsible for miR-
21, miR-30c, and miR-100 transcriptional activation in NSCLC.
Finally, because caspase-8 and TRAF-7 inhibit NF-κB acti-
vation and they are directly down-regulated by miR-21 and miR-
100, we questioned if miR-21 and miR-100 overexpression could
induce NF-κB activation. In this regard, the pGL4.3-luc2p/NF-κB
Fig. 4. NF-κB directly activates miR-21, miR-30c and miR-100. (A) Increased NF-κB promoter activity in H460R cells in response to TRAIL stimulation. NF-κB activity
was assessed by measuring firefly luciferase activity. (B) Western blot analysis showing NF-κB activation in H460R after TRAIL treatment. (C) Cytosol-nucleus
fractionation of H460S and H460R cells to determine NF-κB localization. H460S and H460R cells were treated with 50 ng/mL of TRAIL. After 3 h a cytosol-nucleus
extraction kit (Cell Biolabs) was used to separate nuclear and cytosolic proteins. Anti-tubulin and anti–PARP-1 antibodies were used for cytosolic and nuclear
marker, respectively. (D and E) Volcano plots of NF-κB target genes. Total RNAs of H460S/R (D) and H292S/R (E) were subjected to qRT-PCR in plates equipped with
primer sets for 84 NF-κB target genes. P values were obtained by three independent experiments. Fold-difference is reported as H460R/H460S and H292R/H292S.
(F) Western blot analysis of NF-κB antiapoptotic targets in control and NF-κB knockdown H460S and H460R cells. (G) NF-κB silencing reduces miR-21, miR-30c, and
miR-100 expression levels. The values were normalized with a negative control. Error bars represent mean ± SD (n = 4) and P values were calculated by two-tailed
Student t test or ANOVA test (*P < 0.001). (H) NF-κB activity on miR-21, miR-30c, and miR-100 promoters. The promoter regions of miR-21, miR-30c, or miR-100
containing NF-κB binding sites were subcloned into pGL3-luciferase vectors. The constructs were transfected into H460R cells along with a scrambled or NF-κB p65
siRNA. After 48 h, promoter activity was assessed by measuring firefly luciferase activity. Error bars represent mean ± SD (n = 3) and P values were obtained by
two-tailed Student t test (*P < 0.01). (I) ChIP showing a direct interaction between NF-κB/p65 and miR-21, miR-30c, and miR-100 promoter regions. (J) Increased
phosphorylation of NF-κB/p65 in H460S cells overexpressing miR-21 and miR-100. (K) Coexpression analysis of miRNAs and NF-κB/p65. The images are serial
sections from core 1 (Upper) and core 2 (Lower). Note that the same cancer cells in the top row express miR-21, miR-30c, miR-100, and NF-κB/p65. The cancer cells
in the core in the bottom row do not express both miRNA and the protein. (Magnification, 100×.)














construct was cotransfected along with miR-21 and miR-100 in
H292S cells. Luciferase assays showed an increased luciferase
activity compared with the cells transfected with a scrambled
miRNA (SI Appendix, Fig. S5C). Moreover, immunoblot analysis
displayed an increase in NF-κB phosphorylation after miR-21
and miR-100 enforced expression (Fig. 4J). To test whether this
was a general mechanism and not specific to these cells we an-
alyzed NF-κB phosphorylation levels in cells with primary
TRAIL resistance. Intriguingly, NF-κB phosphorylation was
higher in A549 and Calu-1 compared with the H460S and H292S
cell lines in response to TRAIL stimulation (SI Appendix, Fig.
S5D). Moreover, NF-κB silencing induced a down-regulation of
miR-21, miR-30c, and miR-100 also in the cells with de novo
TRAIL resistance (SI Appendix, Fig. S5 E and F). Importantly,
caspase-8, caspase-3, and TRAF-7 overexpression sensitized also
primary resistant NSCLC cells to TRAIL treatment (SI Appen-
dix, Fig. S5 G–J). To verify the correlation between miRNAs and
NF-κB in lung cancer tissues, in situ hybridization analysis was
performed using 5′-dig–labeled LNA probes for miR-21 and
miR-100 followed by immunohistochemistry analysis for NF-κB/
p65. As shown in Fig. 4K, miR-21, miR-30c, and miR-100
showed strong correlation with NF-κB protein in lung cancer
tissues (Fig. 4K and SI Appendix, Fig. S5K). These data suggest
the activation of NF-κB by miR-21 and miR-100 and the pres-
ence of a positive feedback loop.
NF-κB and TRAIL Signaling. It is known that the TNF receptor-1
associated death-domain protein (TRADD)-TNF-receptor as-
sociated factor (TRAF)-NF-κB signaling cascade acts down-
stream of TRAIL receptors. TRADD has a survival role in
TRAIL signaling and deficiency of TRADD sensitizes cells to
TRAIL-induced apoptosis in innate TRAIL resistance (30).
TRAF-2 has recently been shown to have a positive role in the
canonical pathway that activates NF-κB (23). AKT is one of
the main effectors of NF-κB activation (31, 32). We found an
increased phosphorylation of AKT and ERKs and increased
expression of TRADD and TRAF-2 in H460R and H292R
cells in response to TRAIL stimulation compared with H460S
Fig. 5. Caspase-8–dependent RIP1 cleavage blocks NF-κB activation in TRAIL-resistant cells. (A and B) Increased NF-κB phosphorylation in H460R cells (B) and
not in H460S (A) cells after TRAIL treatment. The sensitive and resistant cells were exposed to 50 ng/mL of TRAIL at the indicated time points. Cells were
harvested and analyzed by Western blot for p-p65, RIP1 cleavage, and caspase-8 activation. (C) MiR-21 knockdown by anti-miR oligonucleotides in H460R cells
reduces p-p65 phosphorylation and increases RIP1 and PARP-1 cleavage. (D and E) Increased NF-κB phosphorylation in H460S (D) and activity in H292S (E) after
caspase-8 knockdown. (F and G) Increased RIP1 cleavage and reduced NF-κB phosphorylation in H460R (F) and activity in H292R (G) cells overexpressing
caspase-8. (H and I) Enforced expression of the C-terminal fragment of RIP1 (tRIP1) inhibit NF-κB activation. pcDNA4-tRIP1-v5 vector were transfected into
H460R cells. After 24 h, cells were stimulated with 50 ng of TRAIL for 2 and 3 h and analyzed byWestern blot (H) and luciferase assay to assess NF-κB activity (I).
Error bars indicate mean ± SD (n = 4) and P values were calculated by ANOVA test (*P < 0.001).
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(SI Appendix, Fig. S6 A–C). Knockdown of TRAF-2, TRADD,
or NF-κB in H460R cells decreased cell survival rate, in-
creased caspase-3/7 activity and induced PARP-1 cleavage (SI
Appendix, Fig. S6 D–F), suggesting that NF-κB–dependent
cell survival signal is conserved in acquired TRAIL-resistant
cells. Interestingly, AKT and not ERKs inhibition sensitized
the resistant cells to TRAIL-induced cell death (SI Appendix,
Fig. S6 G and H).
Caspase 8-Dependent RIP1 Cleavage Plays an Important Role in
Acquired TRAIL Resistance. The death domain kinase RIP1, a key
component of the TNF signaling complex, is cleaved by caspase-8
in TNF-induced apoptosis, resulting in the blockage of TNF-
induced NF-κB activation (10, 13–15, 33). Therefore, we in-
vestigated the role of caspase-8–dependent RIP1 cleavage in the
acquired TRAIL-resistant system. First, H460S cells were ex-
posed to TRAIL at different times for up to 6 h and, as expected,
Fig. 6. Acquired TRAIL resistance induces EMT. (A) Morphological changes in H460R compared with H460S. The phenotype is rescued after NF-κB silencing.
(Scale bar, 20 μm.) (B) Western blot showing EMT markers in H292S and H292R cells. (C) Enhanced migration and invasion capacity of acquired TRAIL-resistant
cells. Bars show mean ± SD (n = 4) and P values were calculated by paired Student t test (*P < 0.02). (D) Anchorage independent growth assay of TRAIL-
resistant cells in response to TRAIL and the NF-κB inhibitor, Bay 117085 treatments. Bars show mean ± SD (n = 3) and P values were calculated by paired
Student t test (*P < 0.01). (E) Growth curve of engrafted tumors injected with H460S and H460R. 1 × 106 of H460S or H460R cells were subcutaneously injected
into three groups of nude mice. One group of the H460R injected mice was treated intraperitoneally with 10 mg/kg of TRAIL for 2 wk. Error bars indicate
mean ± SD (n = 4) and P values were calculated by paired Student t test (*P = 0.022, **P = 0.005, and ***P = 0.003). (F) Growth curve of engrafted tumors in
nude mice injected with H460R cells; 1 × 106 of H460R cells were subcutaneously injected into three groups of nude mice. Next, 5 mg/kg of Bay-117085 were
administered intraperitoneally twice per week for 2 wk and 10 mg/kg of TRAIL were injected intraperitoneally daily for 2 wk. Combination of TRAIL and the NF-κB
inhibitor Bay-117085 reduced tumor volumes compared with a control group treated with PBS and DMSO only. Error bars showmean ± SD (n = 4) and P values were
calculated by paired Student t test (*P = 0.027, **P = 0.006). (G) qRT-PCR showing miR-21, miR-30c, and miR-100 expression in the tumors. Three tumors were isolated
from each group and prepared for qRT-PCR analysis. P values were calculated by ANOVA test or paired Student t test. (*P < 0.001, **P < 0.005, and (***P = 0.011).
(H) Significant phospho-p65 (p-p65) down-regulation in the xenograft tumors treated with TRAIL plus Bay-117085. Tumors from three mice of each group were
minced and analyzed by Western blot with the indicated antibodies. (I) Working model: NF-κB induces acquired TRAIL resistance and EMT through miR-21, miR-30c,
and miR-100 activation. In TRAIL-sensitive cells, the binding of TRAIL to its receptors induces cell death through the canonical caspase-cascade. In cells with acquired
TRAIL-resistance subtoxic concentrations of TRAIL are not enough to induce apoptosis and lead to NF-κB activation, which in turn, transcriptionally regulates miR-21,
miR-30c and miR-100. Down-regulation of caspase-8, casapse-3, FoxO3a and TRAF-7 by these microRNAs causes acquired resistance to TRAIL and EMT.














a decrease in NF-κB phosphorylation and an increase in cleaved
RIP1 and caspase-8 activation starting 4 h after TRAIL-treat-
ment were observed (Fig. 5A). Conversely, RIP1 cleavage and
caspase-8 activation were not detected in H460R cells in re-
sponse to TRAIL stimulation (Fig. 5B). Remarkably, we ob-
served a decrease in NF-κB phosphorylation and enhanced RIP1
cleavage in H460R cells transfected with anti–miR-21 in re-
sponse to TRAIL treatment (Fig. 5C). In addition, phosphory-
lation levels of NF-κB were higher in caspase-8 knockdown
H460S cells (Fig. 5D). Conversely, ectopic expression of pCMV-
caspase-8 in H460R cells suppressed NF-κB phosphorylation and
increased RIP1 cleavage (Fig. 5F). In addition, NF-κB promoter
activity was enhanced in H292S cells transfected with caspase-8
siRNA and reduced in H292R cells overexpressing caspase-8
(Fig. 5 E and G). Finally, we cloned the RIP1 death domain into
a pcDNA4-V5 vector (tRIP1-V5). Overexpression of this con-
struct in H460R cells significantly decreased NF-κB phos-
phorylation (Fig. 5H). Moreover, NF-κB promoter activity was
suppressed in H292R cells after enforced expression of cleaved
RIP1 compared with the cells transfected with an empty vector
(Fig. 5I). MTS and caspase-3/7 assays showed that overex-
pression of RIP1 death domain induced apoptosis in both
H460R and H292R cells (SI Appendix, Fig. S7). Taken together,
these data strongly suggest that caspase-8–dependent RIP1
cleavage driven by miR-21 blocks NF-κB activation in NSCLC
cells with acquired TRAIL resistance and the use of an anti–
miR-21 oligonucleotide can sensitize acquired resistant cells to
TRAIL-induced apoptosis.
Acquired TRAIL Resistance Induces Epithelial-Mesenchymal Transition
and Aggressive Cancer Phenotype. Epithelial-mesenchymal transi-
tion (EMT) is associated with reduced sensitivity to many che-
motherapeutic drugs (34). We observed an impressive change in
cellular shape of H460R cells from an epithelial phenotype to a
spindle-fibroblastoid morphology, which was rescued by the
knockdown of NF-κB (Fig. 6A). Therefore, we further in-
vestigated whether this morphological change could be because
of an EMT. We assessed the expression of key EMT-associated
markers and observed increased expression of mesenchymal
markers and decreased E-cadherin expression (Fig. 6B and SI
Appendix, Fig. S8A). In addition, H460R and H292R showed
higher migratory and invasive capabilities compared with the
parental cells (Fig. 6C and SI Appendix, Fig. S8B). Anchorage-
independent growth is one of the hallmarks of cell trans-
formation. Thus, H460R and H292R were plated in soft agar to
verify their colony formation ability. H460R and H292R cells
presented higher growth rates than their control cells. In-
terestingly, they displayed increased colony growth in response to
TRAIL but the colony growth was dramatically reduced when
they were cotreated with TRAIL and the irreversible NF-κB
inhibitor Bay-117085 (Fig. 6D and SI Appendix, Fig. S8C). Fi-
nally, to analyze tumor growth and the response to TRAIL-
induced apoptosis in vivo, we injected H460S and H460R in the
right side of nude mice. Mice injected with H460R cells pre-
sented tumors slightly but significantly enlarged compared with
those injected with the H460S cells. Furthermore, tumor size
dramatically increased when H460R-injected mice were treated
with TRAIL (Fig. 6E and SI Appendix, Fig. S8D). Of note,
combinatory treatment of TRAIL and Bay-117085 showed a
highly antitumor effect compared with the mice treated only with
the inhibitor (Fig. 6F and SI Appendix, Fig. S8E). The same
results were obtained in mice injected with H292R cells (SI
Appendix, Fig. S8 F and G). MiR-21, miR-30c, and miR-100
expression in the tumor samples was analyzed by qRT-PCR.
MiRNA expression levels were higher in H460R-derived tumors
and reduced in Bay-117085 or Bay-117085 + TRAIL-treated
groups (Fig. 6G). Consistently, NF-κB phosphorylation was re-
duced in the Bay-117085 or Bay-117085 + TRAIL-treated tu-
mors (Fig. 6H). These results indicate that acquired TRAIL
resistance induces a more aggressive cancer phenotype in vitro
and in vivo and the use of NF-κB inhibitors can improve the
response of cancer cells to TRAIL-induced apoptosis.
Our working model summarizes the results of this study. In
TRAIL-sensitive cells, caspase-8 cleaves RIP1; therefore, NF-κB
activation is weak and apoptosis is triggered after TRAIL
treatment. Continuous TRAIL treatment induces constitutive
NF-κB activation, which leads to the accumulation of miR-21,
miR-30c, and miR-100. Caspase-8 and TRAF-7 down-modula-
tion by miR-21 and miR-100 further strengthens the NF-κB
signaling, establishing a positive feedback loop that leads to
TRAIL resistance and EMT (Fig. 6I).
Discussion
Drug resistance is a major obstacle in cancer therapy, and it can
be either intrinsic or acquired during therapy. So far, no strategy
has been found to overcome resistance, which is based on highly
complex and individually variable biological mechanisms. Lung
cancer still represents a very deadly disease in strong need of
new, effective therapeutic approaches. The long-term survival
for patients with advanced high-grade lung cancer has been
limited by the occurrence of resistance to chemotherapeutic
drugs. In this context, TRAIL may represent an alternative
therapeutic molecule. Several TRAIL agonists have been used in
clinical trials showing efficacy in a small fraction of lung cancer
patients (5, 6). However, the majority of NSCLC patients are
resistant or, as with other molecularly targeted agents, resistance
is likely to develop later during therapy. Despite massive studies
for intrinsic TRAIL resistance, the molecular mechanisms un-
derlying the acquired TRAIL resistance is still unclear and little
is known on how lung cancer can acquire resistance to TRAIL
(7, 35). Therefore, it is fundamental to identify biomarkers to
predict the response to the drug and to improve its therapeutic
efficacy, using drug combinations that not only synergize with
TRAIL but that might also overcome resistance as it arises (36).
To understand the mechanisms involved in acquired TRAIL
resistance, we established TRAIL-resistant human isogenic cell
lines (H460R and H292R) from the parental TRAIL-sensitive
(H460S and H292S) cells. Alterations in the expression levels of
TRAIL-R1 and TRAIL-R2 or decoy receptors have been asso-
ciated with the modulation of TRAIL-induced cell death in
different systems (37–39). Both cell lines H460R and H292R had
similar TRAIL receptor expression levels compared with the
corresponding sensitive cells, and did not show any mutation in
their sequences, suggesting that the resistance may be linked to
the alteration of downstream pathways.
miRNAs, single-stranded RNAs of 19–25 nt in length, are key
players in cancer onset and progression. Recent data demon-
strate that selective modulation of miRNA activity can improve
the response to chemotherapy (17, 40). Therefore, we compared
the miRNA expression profile of H460R and H460S cells. Sev-
eral miRNAs, including miR-21, miR-30c, and miR-100, were
found drastically up-regulated in TRAIL-resistant compared
with TRAIL-sensitive cells. miR-21 is a very well-known onco-
miR that inhibits multiple tumor-suppressor genes in different
tumors including NSCLC (41, 42). MiR-30 family is regulated by
EGF and MET receptors, and induces resistance to tyrosine
kinase inhibitors (40). High expression of miR-100 is associated
with poor survival in NSCLC (43). We demonstrated that
enforced expression of miR-21, miR-30c, and miR-100 in
TRAIL-sensitive cells is sufficient to induce resistance to the
drug by directly targeting fundamental tumor-suppressor genes
and effectors of the TRAIL pathway, such as caspase-8, caspase-3,
TRAF-7, and FoxO3a. Noteworthy is that up-regulation of
miR-21, miR-30c, and miR-100 was also observed in NSCLC cell
lines with de novo TRAIL-resistance, suggesting that these
miRNAs may play a role in both the primary and acquired
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TRAIL-resistance. Furthermore, we demonstrated that enforced
expression of miR-21, miR-30c, and miR-100 in TRAIL-sensitive
cells is sufficient to induce resistance to the drug by directly
targeting fundamental tumor-suppressor genes and effectors of
the TRAIL pathway, such as caspase-8, caspase-3, TRAF-7,
and FoxO3a.
Besides inducing apoptosis through the activation of the cas-
pase signaling pathway, TRAIL is also known to activate NF-κB
in innate TRAIL-resistant cells (44, 45). However, the role of
caspase-8 in NF-κB activation is controversial. Caspase-8 is re-
quired for NF-κB activation in HeLa and HEK293 cells in re-
sponse to TNF stimulation (46). Several other studies have
shown that active caspase-8 cleaves RIP1 and cleaved RIP1
prevents NF-κB activation and activates downstream caspases
(13, 14, 33, 47). In lung TRAIL-sensitive cells, RIP1 is cleaved in
a caspase-8–dependent process and is unable to activate NF-κB
signaling. We proved that in acquired TRAIL-resistant cells
down-modulation of caspase-8 by miR-21 blocks RIP1 cleavage,
leading to NF-κB activation and acquired TRAIL-resistance. Of
note, miR-21 knockdown in H460R cells enhanced RIP1 cleav-
age and increased cells sensitivity, demonstrating that modula-
tion of miRNAs is able to revert the sensitivity of cancer cells to
TRAIL treatment. TRAFs were initially discovered as adaptor
proteins that couple the TNF receptor family to signaling path-
ways. A recent study reported that TRAF-7 induces cell death by
repressing NF-κB activation (18). We proved that miR-100, by
down-regulating TRAF-7, induces NF-κB activation in cells with
acquired TRAIL-resistance. Therefore, in the sensitive cells
TRAIL triggers apoptosis through caspase activation and the
NF-κB signaling is weak because of the cleavage of RIP1 by
caspase-8. In the resistant cells, down-modulation of caspase-8
and TRAF-7 by miR-21 and miR-100 activates NF-κB, which in
turn, in a positive feedback loop, induces the transcriptional
activation of miR-21and miR-100. In a previous study we
reported that miR-221/222 induced the activation of the AKT
pathway through phosphatase and tensin homolog deleted on
chromosome 10 silencing, increasing the resistance to TRAIL-
induced apoptosis. Intriguingly, we found an up-regulation of
miR-221 in the H460R cells (Fig. 1C), suggesting that it could
play a role also in acquired TRAIL resistance. As expected, AKT
activation was observed in cells with acquired TRAIL resistance
and inhibition of this pathway sensitized the cells to the drug. Of
note, recent literature reported that AKT is a key regulator of
NF-κB activation and, although initially believed to belong to
distinct signaling pathways, the NF-κB and AKT signaling
pathways can converge (31, 32). It is known that there is a strict
correlation between acquired drug resistance and EMT. Re-
cently, it has been reported that NF-κB constitutive activation is
involved in EMT of NSCLC cells through the up-regulation of
master-switch transcription factors (48). We found a morpho-
logical change and a more aggressive phenotype in H460R and
H292R cells (Fig. 6). Analysis of epithelial and mesenchymal
markers confirmed that acquired TRAIL resistance induced
epithelial to mesenchymal transition in both cell lines. Genetic
inhibition of the NF-κB pathway affects both the initiation and
the maintenance of lung cancer, identifying this pathway as a
promising therapeutic target (49). Remarkably, TRAIL treat-
ment made acquired TRAIL-resistant cells more aggressive but
combinatorial treatment of resistant cells with TRAIL and
NF-κB inhibitors increased apoptosis and reduced cell pro-
liferation in vitro and in vivo, compared with cells treated with
TRAIL or NF-κB inhibitor alone. Taken together, these data
identify NF-κB as a potential companion drug target, together with
TRAIL, in lung cancer and provide insight into the mechanisms by
which tumor cells become resistant to TRAIL-induced apoptosis.
In addition, the results not only suggest that, miR-21, miR-30c, and
miR-100 expression levels could be used as prognostic tool to
predict TRAIL sensitivity or resistance, but also that in the near
future, the delivery and modulation of specific miRNAs could
improve the response of lung cancer patients to TRAIL.
Experimental Procedures
Lung Cancer Samples and Cell Lines. Sixty-nine cancer lung tissues were pur-
chased from US Biomax. Human H460S/R, H292S/R, HEK293, Calu-1, and A549
cell lines were grown in RPMI 1640 containing 10% (vol/vol) heat-inactivated
FBS and with 2 mM L-glutamine and 100 U/mL−1 penicillin–streptomycin.
Western Blot Analysis. Detailed procedures are described in SI Appendix.
MiRNA Locked Nucleic Acid in Situ Hybridization of Formalin-Fixed, Paraffin-
Embedded Tissue Section. In situ hybridizationwas carried out on deparaffinized
human lung tissues using previously a published protocol (50) and de-
scribed in SI Appendix.
Generation of Stable Clones with miR-21, miR-30c, and miR-100 Down-
Regulation. The detailed experimental procedures are described in
SI Appendix.
Soft Agar Colony Formation Assay. The overall procedure of soft agar colony
formation assay was performed according to the manufacturer’s protocol
and detailed procedures are described in SI Appendix.
In Vivo Studies. Animal studies were performed according to institutional
guidelines. The detailed protocols are described in SI Appendix. Animal ex-
periments were conducted after approval of the Institutional Animal Care
and Use Committee, Ohio State University.
Statistical Analysis. Student’s t test and one-way ANOVA were used to de-
termine significance. All error bars represent the SEM. Statistical significance
for all of the tests, assessed by calculating P value, was < 0.05.
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